DEA Tells CBP to Seize Entry in Customs Suit for Containing Controlled Substance
The Drug Enforcement Administration told CBP that it believes importer UniChem's entry of "7-keto dehydroepiandrosterone is a Schedule III anabolic steroid and its importation violates DEA regulations." As a result, DEA requested that CBP seize the entry on DEA's behalf, the U.S. told the Court of International Trade in a June 25 status report (UniChem Enterprises v. U.S., CIT # 24-00033).
Sign up for a free preview to unlock the rest of this article
Export Compliance Daily combines U.S. export control news, foreign border import regulation and policy developments into a single daily information service that reliably informs its trade professional readers about important current issues affecting their operations.
The update came in UniChem's case on its sole entry of 7-keto dehydroepiandrosterone, which was intercepted by DEA on the suspicion that it contained a controlled substance. UniChem says the product is a commonly used dietary supplement, and said CBP has detained the entry for too long without legal authority. CBP moved to dismiss the case for lack of jurisdiction since no protestable decision was made on the entry given that the entry was detained pending a DEA decision (see 2404090029).
In the status report, the government said CBP means to seize the entry on DEA's behalf "no sooner than thirty (30) days from" June 25.